Form 4: Lilly Endowment Sells $38.4M in Eli Lilly Stock

Lilly Endowment Inc., a 10% owner of Eli Lilly & Co., reported the sale of 40,432 shares of common stock totaling approximately $38.47 million through pre-planned transactions.

Summary

• Lilly Endowment Inc., a 10% owner of Eli Lilly & Co. (LLY), reported the sale of 40,432 shares of common stock.
• The transactions occurred on November 5, 2025, with share prices ranging from $947.18 to $955.41.
• The total value of the shares sold is approximately $38,475,121.68.
• Following these transactions, Lilly Endowment Inc. beneficially owns 93,711,978 shares of Eli Lilly & Co. common stock.
• The sales were conducted pursuant to a Rule 10b5-1(c) pre-planned trading arrangement.
• This filing represents transactions #31 through #38 of 38 total transactions, with another Form 4 filed on the same date for earlier transactions.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While it's a significant insider sale, the fact that it's part of a pre-planned 10b5-1 strategy by a 10% owner suggests a routine portfolio management action rather than a negative signal about the company's prospects.

Positives

• The transactions were executed under a Rule 10b5-1(c) plan, indicating a pre-scheduled sale rather than a reaction to immediate market conditions.

Negatives

• A significant insider sale by a 10% owner could be perceived negatively by some investors, although it is part of a pre-planned strategy.

Management Comments

• The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1), (2), (3), (4), (5), (6), (7), and (8) to this Form 4.

Industry Context

This filing reflects a routine insider transaction by a significant shareholder in the pharmaceutical industry. Such sales, especially when pre-planned, are common for large endowments or institutional investors managing diversified portfolios and do not necessarily indicate a change in the company's fundamental outlook or industry trends.

Related Party Transactions

• Lilly Endowment Inc., a 10% owner of Eli Lilly & Co., sold common stock of the issuer. This constitutes a transaction between a related party (significant shareholder) and the company's securities.

Stakeholder Impact

• Shareholders: The sale by a 10% owner could lead to minor short-term price fluctuations due to increased supply, but the pre-planned nature mitigates concerns about negative sentiment.

Key Dates

Recommendation

The reported insider sales by Lilly Endowment Inc. are part of a pre-planned 10b5-1 trading arrangement, indicating a systematic approach to managing their investment rather than a reaction to new material information. While the volume is substantial, it does not suggest a change in the fundamental outlook for Eli Lilly & Co. For investors, this filing provides transparency on a significant shareholder's activity but does not present new information that would warrant a change in investment thesis. Therefore, a 'hold' recommendation is appropriate, maintaining current positions while monitoring future company performance and broader market trends.

Keywords

Eli Lilly, LLY, Lilly Endowment, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, Pharmaceuticals, Biotechnology